Abstract: The current disclosure provides for a method for stratifying patients based on their predicted efficacy to an immunotherapy. Accordingly, provided herein is a method for treating a subject for brain cancer, the method comprising administering to the subject an immunotherapy, wherein the subject has been determined be negative or low for an interferon gamma activation response in a biological sample from the patient. Also described is a method for predicting patient outcomes and/or for predicting the effectiveness of an immunotherapy for treating brain cancer in a subject in need thereof, the method comprising determining an interferon gamma activation response from a biological sample from the subject. Also provided is a method for evaluating a subject having brain cancer, the method comprising determining an interferon gamma activation response in a biological sample from the subject.

Abstract: The current disclosure fulfills a need in the art by providing methods and compositions for treating and vaccinating individuals against cancer. The disclosure describes isolated peptides comprising at least 70% sequence identity to a peptide of one of SEQ ID NOS: 1-107. The peptide may comprise at least 6 contiguous amino acids of a peptide of one of SEQ ID NOS: 1-107. The disclosure also describes a peptide comprising at least 6 contiguous amino acids from a peptide of one of SEQ ID NOS: 1-107, wherein the peptide comprises an alternative splice site junction. Also described is a polypeptide comprising the peptide, pharmaceutical compositions comprising the isolated peptide, nucleic acids encoding the peptide, and expression vectors and host cells comprising the nucleic acids of the disclosure. The nucleic acids of the disclosure include nucleic acids that are RNA or DNA. Also provided is an in vitro isolated dendritic cell comprising a peptide, nucleic acid, or expression vector of the disclosure.

Abstract: This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using TCRs. The current disclosure relates to TCRs that specifically recognize cancer antigens. Also provided are compositions comprising the cells, nucleic acids, or engineered TCRs of the disclosure, methods of making the cells, and methods of using the embodiments of the disclosure for therapeutic treatments.

Abstract: Methods and processes to identify neoplastic tissue antigens derived from alternative splicing (AS) are described, in accordance with various embodiments of the invention. Also described are novel tumor antigens that are useful as targets in various immunotherapeutic approaches to treating brain cancer as well as novel engineered T cell Receptors (TCRs) and chimeric antigen receptors (CARs) that target these antigenic peptides.